Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-11T13:42:39.917Z Has data issue: false hasContentIssue false

Elektroconvulsietherapie (ECT) als behandelmogelijkheid voor motorische symptomen van M. Parkinson

Published online by Cambridge University Press:  11 January 2019

A.F.G. Leentjens*
Affiliation:
Afdeling Psychiatrie, Academisch Ziekenhuis Maastricht
W.W. van den Broek
Affiliation:
Afdeling Psychiatrie, Academisch Ziekenhuis Rotterdam, Dijkzigt
F.W. Vreeling
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis Maastricht
A. Honig
Affiliation:
Afdeling Psychiatrie, Academisch Ziekenhuis Maastricht
*
psychiater, Afdeling Psychiatrie, Academisch Ziekenhuis Maastricht, Postbus 5800, 6202 AZ Maastricht

Samenvatting

Naast de gangbare indicaties voor ECT op het gebied van de affectieve stoornissen, zijn ook positieve effecten van deze behandeling beschreven bij enkele neurologische ziektebeelden. De auteurs geven een overzicht van gepubliceerde onderzoeksresultaten en ziektegeschiedenissen met betrekking tot de effectiviteit van ECT bij de behandeling van motorische symptomen van Parkinson-patiënten met of zonder coëxistente depressieve stoornis. Het enige prospectieve gecontroleerde onderzoek maakt melding van een positief resultaat op de motorische symptomen dat tot zes weken na behandeling aanhoudt. Dit komt overeen met de resultaten van vrijwel alle open onderzoeken en gepubliceerde casus, waarbij verbeteringen beschreven worden, variërend van enkele weken tot vier juar. Twee open onderzoeken (één retrospectief en één prospectief) vinden geen effect op de motoriek.

De aangehaalde literatuur rechtvaardigt volgens de auteurs het opzetten van groter prospectief onderzoek naar de waarde van deze behandeling voor Parkinson-patiënten, en wel met name bij die groep patiënten waarbij de medicamenteuze behandelmogelijkheden uitgeput zijn.

Summary

Summary

The efficacy of ECT as a treatment for severe affective disorders is well known. Less well known is the fact that positive effects of ECT have been described in some neurological disorders as well. The authors review published case-histories and study results regarding the effectiveness of ECT as a treatment for motor symptoms in patients with Parkinson's disease, with or without concurrent depression. The only controlled study that has been published describes an improvement of motor symptoms for up to six weeks after treatment. This is in line with a number of open studies and case-histories, that describe positive effects lasting from several weeks up to four years after discontinuation of ECT treatment. Two open studies (one retrospective and one prospective) report no improvement.

In the authors' opinion, the quoted literature justifies larger controlled studies into the efficacy of ECT as a treatment for motor symptoms in Parkinson's disease, especially in the group of patients for which pharmacological treatment options have been exhausted.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1. Inspectie voor de Gezondheidszorg. Jaarrapportage 1995. Rijswijk: IGZ, 1996.Google Scholar
2. Leentjens, AFG, van den, Broek WW, Birkenhäger, TK. et al. Het effect van medicamenteuse vervolgbehandeling na succesvolle electroconvulsietherapie voor therapieresistente depressie is nog teleurstellend. Ned Tijdschr Geneesk 1996; 140: 241-3.Google Scholar
3. Geneeskundige Hoofdinspectie voor de Geestelijke Volksgezondheid. Richtlijnen Electroconvulsie Therapie (brief). Leidschendam: GHIGV, 1985.Google Scholar
4. Nederlandse Vereniging voor Psychiatric. Electroconvulsieve therapie: aanbevelingen voor indicatiestelling, informed consent en uitvoering (rapport). van, Bemmel AL, Berkestijn, JWB, de, Groot PA, et al, redacteuren. Utrecht: NVP, 1992.Google Scholar
5. Kellner, CH, Bernstein, HJ. ECT as a treatment for neurologic illness. In: Coffey, CE, ed. The clinical Science of electroconvulsive Therapy. Washington D.C.: American Psychiatric Press, 1995: 185-93.Google Scholar
6. Abrams, R. Nonpsychiatric indications for clectroconvulsive therapy. In: Abrams, R. Electroconvulsive therapy; sec ed. Oxford: Oxf Univ Press, 1992: 35-8.Google Scholar
7. Abrams, R. ECT for Parkinson's disease (editorial). Am J Psychiat 1989; 146: 1391-3.Google Scholar
8. Faber, R, Trimble, MR. Electroconvulsive therapy in Parkinson's disease and olher movement disorders. Mov Disord 1991; 6: 293303.Google Scholar
9. Folkerts, H. Elektrokrampftherapie bei neurologischen Krankheiten. Nervenarzt 1995; 66: 241-51.Google Scholar
10. Ben-Shlomo, Y. How far are we in understanding the cause of Parkinsons' disease? J Neurol Neursurg Psychiat 1996; 61: 416.Google Scholar
11. Koller, WC, Silver, DE, Lieberman, A. An algorithm for the management of Parkinson's disease. Neurology 1994; 44(suppl 10): 152.Google Scholar
12. Quinn, N. Drug treatment in Parkinson's disease. Brit Med J 1995; 310: 575-9.Google Scholar
13. Marsden, CD. Parkinson's disease. J Neurol Neurosurg Psychiat 1994; 57: 672-81.Google Scholar
14. Gancher, ST, Nutt, JG, Woodward, WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991; 6: 212-6.Google Scholar
15. van, Laar T. Pharmacokinetics and clinical efficay of apomorphine in patients with Parkinson's disease. Leiden: Proefschrift, 1996.Google Scholar
16. Hardie, RJ, Lees, AJ, Stern, GM. On-off fluctuations in Parkinson's disease. Brain 1984; 107: 487506.Google Scholar
17. Maier Hoehn, MM. Parkinson's disease: progression and mortality. In: Yahr, MD Bergman, KJ, eds. Advances in Neurology, vol 45. New York: Raven Press, 1986: 457-61.Google Scholar
18. Lebensohn, ZM, Jenkins, RB. Improvement of parkinsonism in depressed patients treated with ECT. Am J Psychiat 1975; 132: 283-5.Google Scholar
19. Lebensohn, ZM. Parkinsonism, depression, and ECT (letter). Am J Psychiat 1975; 132: 1084.Google Scholar
20. Lipper, S, Bermanzohn, PC. Electroconvulsive therapy in patients with parkinsonism (letter). Am J Psychiat 1975; 132:457.Google Scholar
21. Asnis, G. Parkinson's disease, depression, and ECT: a review and case study. Am J Psychiat 1977: 134: 191-5.Google Scholar
22. Yudofsky, SC. Parkinson's disease, depression and electroconvulsive therapy: a clinical and neurobiologic synthesis. Compr Psychiat 1979; 20: 579-81.Google Scholar
23. Levy, LA, Savit, JM, Hodes, M. Parkinsonism: improvement by electroconvulsive therapy. Arch phys med Rehabil 1983; 64: 432-3.Google Scholar
24. Holcomb, HH, Sternberg, DE, Heninger, GR. Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and the dopamine systems. Biol Psychiat 1983; 18: 865-73.Google Scholar
25. Young, RC, Alexopoulos, GS, Shamoian, CA. Dissociation of motor response from mood and cognition in a parkinsonian patient treated with ECT. Biol. Psychiat 1985; 20: 566-9.Google Scholar
26. Burke, WJ, Peterson, J, Rubin, EH. Electroconvulsive therapy in the treatment of combined depression and Parkinson's disease. Psychosomalics 1988; 29: 341-6.Google Scholar
27. Birkett, DP. ECT in parkinsonism with affective disorder (letter). Br J Psychiat 1988; 152: 712.Google Scholar
28. Douyon, R, Serby, M, Klutchko, B, Rotrosen, J. ECT and Parkinson's disease revisited: a ‘naturalistic’ study. Am J Psychiat 1989; 146: 1451-5.Google Scholar
29. Oh, JJ, Rummans, TA, O'Connor, MK, Ahlskog, J. Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness (letter). Am J Psychiat 1992; 149: 271.Google Scholar
30. Sweet, RD, McDowell, FH. The ‘on-off response to chronic L-DOPA in Parkinson's disease. Adv Neurol 1974; 5: 331-8.Google Scholar
31. Balldin, J, Eden, S, Granerus, A-K, et al. Electroconvulsive therapy in Parkinson's syndrome with ‘on-off’ phenomenon. J neur Transm 1980; 47: 11-21.Google Scholar
32. Balldin, J, Granerus, A-K, Lindstedt, G. Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms. J neur Transm 1981; 52: 199-21 1.Google Scholar
33. Duvoisin, RC. The evaluation of extrapyramidal disease. In: Monoamines, Noyeaux gris centraux et syndrome de Parkinson. Aguraguerra, J, Gauthier, G, George, C, ed. Paris: Masson, 1971: 313-25.Google Scholar
34. Simpson, GM, Angus, JWS. A rating scale for extrapyramidal side effects. Acta psychiat scand 1970; suppl 212: 11-9.Google Scholar
35. Granerus, A-K. Factors influencing the occurence of ‘on-off’ symptoms during long term treatment with L-DOPA. Acta med scand 1972; 192: 111.Google Scholar
36. Guy, W, editor. ECDEU Assessment manual. Washington DC: US Dept of Health, Education and Welfare. 1976: 534-7.Google Scholar
37. Webster, DD. Critical analysis of disability in Parkinson's disease. Mod Ther 1968; 5: 257-82.Google Scholar
38. Lieberman, A, Dziatocowski, M, Gopinathan, G, et al. Evaluation of Parkinson's Disease. In: Goldstein, M, Calne, D, Lieberman, A, et al., eds. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven Press, 1980.Google Scholar
39. Ward, C, Stern, GM, Pratt, RTC, et al. Electroconvulsive therapy in parkinsonian patients with the ‘on-off’ syndrome. J neur Transm 1980; 49: 133-5.Google Scholar
40. Andersen, K, Balldin, J, Gottfries, CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with ‘on-off’ phenomena. Acta neurol scand 1987; 76: 191-9.Google Scholar
41. Berger, M. The use of ECT for Parkinson symptoms in a nondepressed patient (letter). Psychosomatics 1990; 31: 465-6.Google Scholar
42. Pridmore, S, Yeo, PT, Pasha, MI. Electroconvulsive therapy for the physical signs of Parkinson's disease without depressive disorder (letter). J Neurol Neurosurg Psychiat 1995; 58: 641-2.Google Scholar
43. Pridmore, S, Pollard, C. Electroconvulsive therapy in Parkinson's disease: a 30 month follow up (letter). J Neurol Neurosurg Psychiat 1996; 61: 693.Google Scholar
44. Fahn, S, Elton, RL and members of the UPDRS committee. Unified Parkinson's Disease Rating Scale. In: Fahn, S, Marsdcn, CD, Goldstein, M, Calne, DB, eds. Recent developments in Parkinson's disease. Vol 2. New Jersey: McMillan Health Care, 1987: 153-63.Google Scholar
45. Carter, CJ, Thorne, R, Mier, M. A method of evaluating disability in patients with Parkinson's disease. J nerv ment Dis 1961; 133: 143-7.Google Scholar
46. Hoehn, MM, Yahr, MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.Google Scholar
47. Kellner, CH, Beale, MD, Pritchett, JT, CM, , et al. Electroconvulsive therapy Bernstein HJ. Burns and Parkinson's disease: the case for further study. Psychopharm Bull 1994; 30: 495-500.Google Scholar
48. Rasmussen, K, Abrams, R. Treatment of Parkinson's disease with electroconvulsive therapy. Psychiat Clin North Am 1991; 14(4): 925-33.Google Scholar
49. Figiel, GS, Hassen, MA, Zorumski, C, et al. ECT induced delirium in depressed patients with Parkinson's disease. J Neuropsychiat clin Neurosc 1991; 3: 405-11.Google Scholar
50. Fink, M, Zervas, IM. ECT and delirium in Parkinson's disease (letter). J Neuropsychiat clin Neurosci 1992; 4: 231-2.Google Scholar
51. Lemstra, A, Leentjens, AFG, van den, Broek WW. Slechts tijdelijke resultaten van electroconvulsietherapie bij therapieresistente depressie: retrospectief onderzoek. Ned Tijdschr Geneesk 1986; 149: 260-4.Google Scholar
52. Zervas, IM, Fink, M. ECT for refractory Parkinson's disease (letter). Conv Ther 1991; 7: 222-3Google Scholar
53. Leentjens, AFG, van den, Broek WW. M. Parkinson en depressie. Acta neuropsychiat 1993; 5: 83-7.Google Scholar
54. van, Praag HM, Asnis, GM. Kahn, RS, et al. Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiat 1990; 157: 723-34Google Scholar
55. Fochtman, L. A mechanism for the efficacy of ECT in Parkinson's disease. Conv Ther 1988; 4: 321-7.Google Scholar
56. Sandyk, R. ECT, opioids, and motility in Parkinson's disease (letter). Biol Psychiat 1986; 21: 425-9.Google Scholar